Search
Now showing items 1-2 of 2
Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study
(BMC Infectious Diseases, 2013)
Background: HIV infection, anti-tuberculosis and efavirenz therapy are associated with neuropsychological effects.
We evaluated the influence of rifampicin cotreatment, efavirenz pharmacokinetics and pharmacogenetics ...
CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population
(Future Medicine Ltd: Pharmacogenomics, 2016)
To assess genotype effect on efavirenz (EFV) pharmacokinetics, treatment
outcomes and provide genotype-based EFV doses recommendations during for
tuberculosis (TB)-HIV-1 cotreatment. Materials & methods: EFV concentrations
from ...